K

PriceKazia Therapeutics

KZIA

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

Historical stock price chart and annual return over the past years

-97%

5 years

% Total

KZIA
-50%

5 years

Annual Return

KZIA